1 / 7

XVIVO Perfusion

XVIVO Perfusion. Petra Apell Magnus Nilsson. Our focus Nobody should die waiting for a new organ. Our mission To help transplantation teams save lives. Our strategy Dedicated team members. Involving leading clinics and scientists in innovative research collaborations.

quinlan-rutledge
Download Presentation

XVIVO Perfusion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. XVIVO Perfusion Petra ApellMagnus Nilsson

  2. Our focusNobodyshoulddiewaiting for a new organ. Our mission To help transplantation teams save lives. OurstrategyDedicated team members. Involving leading clinics and scientists in innovative research collaborations.

  3. XVIVOhistory XVIVO Transplantation founded by Dr. M. Nilsson Separateentity, Dr. M. Nilsson CEOofXVIVO NOVEL trial Intention toTreat7 centres Listed on NASDAQ OMX First North STEEN Solution CE marked PerfadexFDA clearance Mergedwith Vitrolife AB 2001 2006 2000 2007 1999 2013 1998 2012 International breakthroughEVLP Research collaboration Dr ShafKeshavjee Firstlung transplant using ex vivowith STEEN Solution1 140 EVLP LTxConversion 81,5%2 • Research collaboration Prof Stig Steen 1. Steen S et al. Transplantation of lungs from a non-heart –beating donor. Lancet 2001, Mar 17;357:825-829.2. CypelM, Aigner C, Sage E, et al. Presented at ISHLT 2013..

  4. XVIVOtoday Aseptic manufacturing & quality control Core business biomedicine innovations Approved products Preclinical and clinical research collaborations World-widedistribution

  5. Stem cell therapy XVIVOfuture IVLP Other organs Tissueengineering STEEN Solution and XPSFDA clearance New Medical Advisor Dr. Joel Cooper XPS launchin Europe 2013 2014 Newcastle Oct 25

  6. LTx – lookinginto the crystal ball

  7. Change is inevitable. Progress is optional.

More Related